Ganli Pharmaceutical

Gan &a; Lee pharmaceutical is a Chinese high-tech biopharmaceutical company engaged in the R&a;D of insulin glargine and insulin lispro.

Business Model:

Revenue: $0

Employees: 1,001-5,000

Rankings

Detailed Ganli Pharmaceutical Information

Geographic Data

Ganli Pharmaceutical headquarters map

Address: No. 8 Jingsheng North 3rd Street

City: Beijing

State: beijing municipality

Zip: 101102

Country: CN

Financial Info

Stage:

private equity

Raised Last:

$0

Raised Total:

$46M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Founded in 1998, Gan &a; Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan &a; Lee has been focusing on insulin production. In 1998, Gan &a; Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan &a; Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.

Contact Phone:

Contact Email:

Ganli Pharmaceutical went public on 6/28/2020 on the Shanghai Stock Exchange

Listed Exchange:
Shanghai Stock Exchange

IPO Date:
6/28/2020

Ticker Symbol:
603087

IPO Price:
$63.32/share

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
11/2021 Sepax Technologies Series D 0
11/2021 Sepax Technologies Series D 0
Announced Date Transaction Number of Investors Money Raised Lead Investors
1/2015 Private Equity Round 1 - Hillhouse Capital Group
Hillhouse Capital Group
12/2009 Series A 1 $16.2M Qiming Venture Partners
Qiming Venture Partners
5/2011 Series B 3 $30.2M Goldman Sachs
Qiming Venture Partners
Tengye Ventures
Goldman Sachs
Qiming Venture Partners
Tengye Ventures
6/2020 IPO $360M
2/2012 Series B 1 - Qiming Venture Partners
Qiming Venture Partners
1/2015 Private Equity Round 1 - Hillhouse Capital Group
Hillhouse Capital Group
2/2012 Series B 1 - Qiming Venture Partners
Qiming Venture Partners
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research